At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Nov 9, 2026 at 07:00 ET
Tango Therapeutics reported Q3 2026 net loss of $68.4M ($0.39/share) vs net income of $15.9M ($0.14/share) in Q3 2025, driven by higher R&D and G&A expenses and the end of Gilead collaboration revenue. Cash stood at $977.5M. The key catalyst was promising Phase 1/2 data for vopimetostat plus daraxonrasib in pancreatic cancer (82% ORR, 88% 9-month PFS), with plans for a Phase 3 registrational study in 1H 2027 and potential accelerated approval discussions.
- Net loss Q3 2026: $68.4M ($0.39/share) vs net income $15.9M ($0.14/share) in Q3 2025
- Cash, cash equivalents and marketable securities: $977.5M as of Sep 30, 2026
- Collaboration revenue: $0 in Q3 2026 vs $53.8M in Q3 2025 (Gilead deal ended)
- R&D expenses: $48.9M in Q3 2026 vs $30.8M in Q3 2025
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access